Araştırma Makalesi
BibTex RIS Kaynak Göster

Yıl 2025, Cilt: 29 Sayı: 3, 1089 - 1097, 04.06.2025

Busra Nur Cattik , Nilay Aksoy , Barkın Berk , Barış Güngör

https://doi.org/10.12991/jrespharm.1694236

Öz

Kaynakça

  • [1] Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A,Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC,Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–e1032 https://doi.org/10.1161/CIR.0000000000001063.
  • [2] McDonagh TA, Metra M, Adamo A, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. https://doi.org/10.1093/eurheartj/ehab368.
  • [3] Shirazi LF, Bissett J, Romeo F, Mehta JL. Role of inflammation in heart failure. Curr Atheroscler Rep. 2017;19:27. https://doi.org/10.1007/s11883-017-0660-3.
  • [4] Dick SA, Epelman S. Chronic heart failure and inflammation. Circ Res. 2016;119:159–176. https://doi.org/10.1161/CIRCRESAHA.116.308030.
  • [5] Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB, Intermountain Heart Collaborative (IHC) Study Group. Which white blood cell subtypes predict increased cardiovascular risk?. J Am Coll Cardiol. 2005;45(10):1638-1643. https://doi.org/10.1016/j.jacc.2005.02.054.
  • [6] Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, Meghani M, Akhtar M, Costantino T. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013;11(1):55-59. https://doi.org/10.1586/erc.12.159.
  • [7] IJsselmuiden AJ, Musters RJ, de Ruiter G, van Heerebeek L, Alderse-Baas F, van Schilfgaarde M, Leyte A, Tangelder G, Laarman GJ, Paulus WJ. Circulating white blood cells and platelets amplify oxidative stress in heart failure. Nat Clin Pract Cardiovasc Med. 2008;5(12):811-820. https://doi.org/10.1038/ncpcardio1364.
  • [8] Benites-Zapata VA, Hernandez AV, Nagarajan V, Cauthen CA, Starling RC, Tang WH. Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure. Am J Cardiol. 2015;115(1):57-61. https://doi.org/10.1016/j.amjcard.2014.10.008.
  • [9] Durmus E, Kivrak T, Gerin F, Sunbul M, Sari I, Erdogan O. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of heart failure. Arq Bras Cardiol. 2015;105:606–613. https://doi.org/10.5935/abc.20150126.
  • [10] Lang CC, Mohan M, Levin D, Choy AM, Struthers AD. Prognostic role of combined platelet count and neutrophil-to-lymphocyte ratio in predicting outcome in patients with chronic heart failure. J Am Coll Cardiol. 2015;65:217–228. https://doi.org/10.1016/S0735-1097(15)61005-1
  • [11] Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SPA, Remaley AT, Sviridov D, Chin-Dusting J. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008;28:2071–2077. https://doi.org/10.1161/ATVBAHA.108.168690.
  • [12] Hafiane A, Genest J. High-density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin. 2015;3:175–188. https://doi.org/10.1016/j.bbacli.2015.01.005.
  • [13] Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, Karaman M, Oguz Y, Eyileten T, Vural A, Covic A, Goldsmith D, Turak O, Yilmaz MI. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014;46:1619–1625. https://doi.org/10.1007/s11255-014-0730-1.
  • [14] Canpolat U, Aytemir K, Yorgun H, Şahiner L, Kaya EB, Çay S, Topaloğlu S, Aras D, Oto A. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace 2015;17:1807–1815. https://doi.org/10.1093/europace/euu291.
  • [15] Cetin EHO, Cetin MS, Canpolat U, Aydin S, Topaloglu S, Aras D, Aydogdu S. Monocyte/HDL-cholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Biomark Med 2015;9:967–977. https://doi.org/10.2217/bmm.15.74.
  • [16] Kundi H, Gok M, Kiziltunc E, Cetin M, Cicekcioglu H, Cetin ZG, Karayigit O, Ornek E Relation between monocyte to high-density lipoprotein cholesterol ratio with presence and severity of isolated coronary artery ectasia. Am J Cardiol. 2015;116:1685–1689. https://doi.org/10.1016/j.amjcard.2015.08.036.
  • [17] Kundi H, Kiziltunc E, Cetin M, Cicekcioglu H, Cetin ZG, Cicek G, Ornek E. Association of monocyte/HDL-C ratio with SYNTAX scores in patients with stable coronary artery disease. Herz. 2016;41:523–529. https://doi.org/10.1007/s00059-015-4393-1.
  • [18] Inonu Koseoglu H, Pazarli AC, Kanbay A, Demir O. Monocyte Count/HDL cholesterol ratio and cardiovascular disease in patients with obstructive sleep apnea syndrome: A multicenter study. Clin Appl Thromb 2018;24:139–144. https://doi.org/10.1177/1076029616677803.
  • [19] Sirin MC, Korkmaz S, Erturan I, Filiz B, Aridogan BC, Cetin ES, Yildirim M. Evaluation of monocyte to HDL cholesterol ratio and other inflammatory markers in patients with psoriasis. An Bras Dermatol 2020;95:575–582. https://doi.org/10.1016/j.abd.2020.02.008.
  • [20] Avci A, Biricik S, Avci BS, Yesiloglu O, Sumbul HE, Icme F, Koca H, Cinar H, Koc M, Satar S. The new prognostic factor for pulmonary embolism: The ratio of monocyte count to HDL cholesterol. Am J Emerg Med 2021;46:212–216. https://doi.org/10.1016/j.ajem.2020.07.026.
  • [21] Jiang M, Yang J, Zou H, Li M, Sun W, Kong X. Monocyte-to-high-density lipoprotein-cholesterol ratio (MHR) and the risk of all-cause and cardiovascular mortality: a nationwide cohort study in the United States. Lipids Health Dis 2022;21:30. https://doi.org/10.1186/s12944-022-01638-6.
  • [22] Cabassi A, Champlain J de, Maggiore U, Parenti E, Coghi P, Vicini V, Tedeschi S, Cremaschi E, Binno S, Rocco R, Bonali S, Bianconcini M, Guerra C, Folesani G, Montanari A, Regolisti G, Fiaccadori E. Prealbumin improves death risk prediction of BNP-added Seattle Heart Failure Model: Results from a pilot study in elderly chronic heart failure patients. Int J Cardiol 2013;168:3334–3339. https://doi.org/10.1016/j.ijcard.2013.04.039.
  • [23] Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AHB, Goldberg LR, Jessup M, Cappola TP. Multiple biomarkers for risk prediction in chronic heart failure. Circ Hear Fail. 2012;5:183–190. https://doi.org/10.1161/CIRCHEARTFAILURE.111.965020.
  • [24] Wedel H, McMurray JJV, Lindberg M, Wikstrand J, Cleland JGF, Cornel JH, Dunselman P, Hjalmarson Å, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F. Predictors of fatal and non‐fatal outcomes in the controlled rosuvastatin multinational trial in heart failure (CORONA): Incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide. Eur J Heart Fail 2009;11:281–291. https://doi.org/10.1093/eurjhf/hfn046.
  • [25] Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model. Circulation 2006;113:1424–1433. https://doi.org/10.1161/CIRCULATIONAHA.105.584102.
  • [26] Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJV, Swedberg KB, Östergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65–75. https://doi.org/10.1093/eurheartj/ehi555.
  • [27] Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Køber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404–1413. https://doi.org/10.1093/eurheartj/ehs337.
  • [28] Rogers RK, Stoddard GJ, Greene T, Michaels AD, Fernandez G, Freeman A, Nord J, Stehlik J. Usefulness of adjusting for clinical covariates to improve the ability of B-Type natriuretic peptide to distinguish cardiac from noncardiac dyspnea. Am J Cardiol. 2009;104:689–694. https://doi.org/10.1016/j.amjcard.2009.04.043.
  • [29] Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol Ser A Biol Sci Med Sci. 2014;69:S4–S9. https://doi.org/10.1093/gerona/glu057.
  • [30] Porter Starr KN, Orenduff M, McDonald SR, Mulder H, Sloane R, Pieper CF, Bales CW Influence of weight reduction and enhanced protein intake on biomarkers of inflammation in older adults with obesity. J Nutr Gerontol Geriatr. 2019;38:33–49. https://doi.org/10.1080/21551197.2018.1564200.
  • [31] Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13:851–863. https://doi.org/10.5114/aoms.2016.58928.
  • [32] Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PWF, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594–600. https://doi.org/10.1161/01.CIR.0000112582.16683.EA.
  • [33] Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH, de Lemos JA. Impact of body mass and body composition on circulating levels of natriuretic peptides. Circulation. 2005;112:2163–2168. https://doi.org/10.1161/CIRCULATIONAHA.105.555573.
  • [34] Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J. 2005;149:744–750. https://doi.org/10.1016/j.ahj.2004.07.010.
  • [35] Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation: Comparison of the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM). J Hear Lung Transplant. 2011;30:1236–1243. https://doi.org/10.1016/j.healun.2011.05.012.
  • [36] Lamblin N, Mouquet F, Hennache B, Dagorn J, Susen S, Bauters C, de Groote P. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J. 2005;26:2245–2250. https://doi.org/10.1093/eurheartj/ehi501.
  • [37] Yin W-H, Chen J-W, Jen H-L, Chiang M-C, Huang W-P, Feng A-N, Young MS, Lin S-J Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J. 2004;147:931–938. https://doi.org/10.1016/j.ahj.2003.11.021.
  • [38] Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN. C-Reactive Protein in Heart Failure. Circulation. 2005;112:1428–1434. https://doi.org/10.1161/CIRCULATIONAHA.104.508465
  • [39] Araújo JP, Lourenço P, Azevedo A, Friões F, Rocha-Gonçalves F, Ferreira A, Bettencourt P. Prognostic value of high-sensitivity C-Reactive protein in heart failure: A systematic review. J Card Fail. 2009;15:256–266. https://doi.org/10.1016/j.cardfail.2008.10.030.
  • [40] Masson S, Vago T, Baldi G, Salio M, Angelis N De, Nicolis E, Maggioni AP, Latini R, Norbiato G, Bevilacqua M. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med. 2002;40:761–763. https://doi.org/10.1515/CCLM.2002.130.
  • [41] Kuster GM, Tanner H, Printzen G, Suter TM, Mohacsi P HO. B-type natriuretic peptide for diagnosis and treatment of congestive heart failure. Swiss Med Wkly. 2002;132:623–628. https://doi.org/10.4414/smw.2002.10081.
  • [42] Song BG, Jeon ES, Kim YH, Kang MK, Doh JH, Kim PH, Ahn SJ, Oh HL, Kim H-J, Sung JD, Lee SC, Gwon HC, Kim JS, Kim D-K, Lee SH, Hong KP, Park JE, Lee SY, Lee JK. Correlation Between Levels of N-terminal Pro-B-Type Natriuretic Peptide and Degrees of Heart Failure. Korean J Intern Med. 2005;20:26–32. https://doi.org/10.3904/kjim.2005.20.1.26.
  • [43] Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JGF Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J. 2007;153:1048–1055. https://doi.org/10.1016/j.ahj.2007.03.044.
  • [44] Radenovic S, Loncar G, Busjahn A, Apostolovic S, Zdravkovic M, Karlicic V, Veskovic J, Tahirovic E, Butler J, Düngen H-D. Systemic inflammation and functional capacity in elderly heart failure patients. Clin Res Cardiol. 2018;107:362–367. https://doi.org/10.1007/s00392-017-1195-x.
  • [45] Shah SJ, Marcus GM, Gerber IL, Mckeown BH, Vessey JC, Jordan M V., Huddleston M, Foster E, Chatterjee K, Michaels AD. High-Sensitivity C-Reactive Protein and Parameters of Left Ventricular Dysfunction. J Card Fail. 2006;12:61–65. https://doi.org/10.1016/j.cardfail.2005.08.003.

The association between monocyte/HDL-C ratio and heart failure

Yıl 2025, Cilt: 29 Sayı: 3, 1089 - 1097, 04.06.2025

Busra Nur Cattik , Nilay Aksoy , Barkın Berk , Barış Güngör

https://doi.org/10.12991/jrespharm.1694236

Öz

The monocyte/HDL-cholesterol ratio (MHR) was shown to be a marker of inflammation. This study investigated the utilization of this ratio as a measure of severity for heart failure which is a condition associated with inflammation. The MHR was calculated for 323 ambulatory patients with chronic heart failure and compared to other variables associated with the severity of the condition. Additionally, the impact of MHR on the Seattle Heart Failure Model (SHFM) score was investigated. MHR correlated positively with C-reactive protein (r: 0.312, p<0.001) and neutrophil-to-lymphocyte ratio (r: 0.242, p<0.001), but not with platelet-to-lymphocyte ratio. In addition, a correlation was found between the SHFM score and MHR (r:-0.267, p<0.001). The SHFM score exhibited a significant result for proBtype natriuretic peptide (pro-BNP) (p<0.001), neutrophil (p<0.001), hematocrit (p=0.001), and serum creatinine (p=0.001) in the ordinal logistic regression analysis, but not for MHR. MHR showed a negative correlation with left ventricular ejection fraction (r: -0.151, p: 0.007), exhibited a positive association with pro-BNP (r: 0.184, p<0.001), and no correlation with New York Heart Association classes. There is a significant correlation between the MHR value and the factors associated with the severity of heart failure. The prognosis and management of this condition may be assessed by utilizing the MHR value in conjunction with existing biomarkers.

Anahtar Kelimeler

HDL-cholesterol heart failure ınflammation MHR monocyte

Kaynakça

  • [1] Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A,Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC,Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–e1032 https://doi.org/10.1161/CIR.0000000000001063.
  • [2] McDonagh TA, Metra M, Adamo A, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. https://doi.org/10.1093/eurheartj/ehab368.
  • [3] Shirazi LF, Bissett J, Romeo F, Mehta JL. Role of inflammation in heart failure. Curr Atheroscler Rep. 2017;19:27. https://doi.org/10.1007/s11883-017-0660-3.
  • [4] Dick SA, Epelman S. Chronic heart failure and inflammation. Circ Res. 2016;119:159–176. https://doi.org/10.1161/CIRCRESAHA.116.308030.
  • [5] Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB, Intermountain Heart Collaborative (IHC) Study Group. Which white blood cell subtypes predict increased cardiovascular risk?. J Am Coll Cardiol. 2005;45(10):1638-1643. https://doi.org/10.1016/j.jacc.2005.02.054.
  • [6] Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, Meghani M, Akhtar M, Costantino T. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013;11(1):55-59. https://doi.org/10.1586/erc.12.159.
  • [7] IJsselmuiden AJ, Musters RJ, de Ruiter G, van Heerebeek L, Alderse-Baas F, van Schilfgaarde M, Leyte A, Tangelder G, Laarman GJ, Paulus WJ. Circulating white blood cells and platelets amplify oxidative stress in heart failure. Nat Clin Pract Cardiovasc Med. 2008;5(12):811-820. https://doi.org/10.1038/ncpcardio1364.
  • [8] Benites-Zapata VA, Hernandez AV, Nagarajan V, Cauthen CA, Starling RC, Tang WH. Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure. Am J Cardiol. 2015;115(1):57-61. https://doi.org/10.1016/j.amjcard.2014.10.008.
  • [9] Durmus E, Kivrak T, Gerin F, Sunbul M, Sari I, Erdogan O. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of heart failure. Arq Bras Cardiol. 2015;105:606–613. https://doi.org/10.5935/abc.20150126.
  • [10] Lang CC, Mohan M, Levin D, Choy AM, Struthers AD. Prognostic role of combined platelet count and neutrophil-to-lymphocyte ratio in predicting outcome in patients with chronic heart failure. J Am Coll Cardiol. 2015;65:217–228. https://doi.org/10.1016/S0735-1097(15)61005-1
  • [11] Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SPA, Remaley AT, Sviridov D, Chin-Dusting J. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008;28:2071–2077. https://doi.org/10.1161/ATVBAHA.108.168690.
  • [12] Hafiane A, Genest J. High-density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin. 2015;3:175–188. https://doi.org/10.1016/j.bbacli.2015.01.005.
  • [13] Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, Karaman M, Oguz Y, Eyileten T, Vural A, Covic A, Goldsmith D, Turak O, Yilmaz MI. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014;46:1619–1625. https://doi.org/10.1007/s11255-014-0730-1.
  • [14] Canpolat U, Aytemir K, Yorgun H, Şahiner L, Kaya EB, Çay S, Topaloğlu S, Aras D, Oto A. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace 2015;17:1807–1815. https://doi.org/10.1093/europace/euu291.
  • [15] Cetin EHO, Cetin MS, Canpolat U, Aydin S, Topaloglu S, Aras D, Aydogdu S. Monocyte/HDL-cholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Biomark Med 2015;9:967–977. https://doi.org/10.2217/bmm.15.74.
  • [16] Kundi H, Gok M, Kiziltunc E, Cetin M, Cicekcioglu H, Cetin ZG, Karayigit O, Ornek E Relation between monocyte to high-density lipoprotein cholesterol ratio with presence and severity of isolated coronary artery ectasia. Am J Cardiol. 2015;116:1685–1689. https://doi.org/10.1016/j.amjcard.2015.08.036.
  • [17] Kundi H, Kiziltunc E, Cetin M, Cicekcioglu H, Cetin ZG, Cicek G, Ornek E. Association of monocyte/HDL-C ratio with SYNTAX scores in patients with stable coronary artery disease. Herz. 2016;41:523–529. https://doi.org/10.1007/s00059-015-4393-1.
  • [18] Inonu Koseoglu H, Pazarli AC, Kanbay A, Demir O. Monocyte Count/HDL cholesterol ratio and cardiovascular disease in patients with obstructive sleep apnea syndrome: A multicenter study. Clin Appl Thromb 2018;24:139–144. https://doi.org/10.1177/1076029616677803.
  • [19] Sirin MC, Korkmaz S, Erturan I, Filiz B, Aridogan BC, Cetin ES, Yildirim M. Evaluation of monocyte to HDL cholesterol ratio and other inflammatory markers in patients with psoriasis. An Bras Dermatol 2020;95:575–582. https://doi.org/10.1016/j.abd.2020.02.008.
  • [20] Avci A, Biricik S, Avci BS, Yesiloglu O, Sumbul HE, Icme F, Koca H, Cinar H, Koc M, Satar S. The new prognostic factor for pulmonary embolism: The ratio of monocyte count to HDL cholesterol. Am J Emerg Med 2021;46:212–216. https://doi.org/10.1016/j.ajem.2020.07.026.
  • [21] Jiang M, Yang J, Zou H, Li M, Sun W, Kong X. Monocyte-to-high-density lipoprotein-cholesterol ratio (MHR) and the risk of all-cause and cardiovascular mortality: a nationwide cohort study in the United States. Lipids Health Dis 2022;21:30. https://doi.org/10.1186/s12944-022-01638-6.
  • [22] Cabassi A, Champlain J de, Maggiore U, Parenti E, Coghi P, Vicini V, Tedeschi S, Cremaschi E, Binno S, Rocco R, Bonali S, Bianconcini M, Guerra C, Folesani G, Montanari A, Regolisti G, Fiaccadori E. Prealbumin improves death risk prediction of BNP-added Seattle Heart Failure Model: Results from a pilot study in elderly chronic heart failure patients. Int J Cardiol 2013;168:3334–3339. https://doi.org/10.1016/j.ijcard.2013.04.039.
  • [23] Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AHB, Goldberg LR, Jessup M, Cappola TP. Multiple biomarkers for risk prediction in chronic heart failure. Circ Hear Fail. 2012;5:183–190. https://doi.org/10.1161/CIRCHEARTFAILURE.111.965020.
  • [24] Wedel H, McMurray JJV, Lindberg M, Wikstrand J, Cleland JGF, Cornel JH, Dunselman P, Hjalmarson Å, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F. Predictors of fatal and non‐fatal outcomes in the controlled rosuvastatin multinational trial in heart failure (CORONA): Incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide. Eur J Heart Fail 2009;11:281–291. https://doi.org/10.1093/eurjhf/hfn046.
  • [25] Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model. Circulation 2006;113:1424–1433. https://doi.org/10.1161/CIRCULATIONAHA.105.584102.
  • [26] Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJV, Swedberg KB, Östergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65–75. https://doi.org/10.1093/eurheartj/ehi555.
  • [27] Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Køber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404–1413. https://doi.org/10.1093/eurheartj/ehs337.
  • [28] Rogers RK, Stoddard GJ, Greene T, Michaels AD, Fernandez G, Freeman A, Nord J, Stehlik J. Usefulness of adjusting for clinical covariates to improve the ability of B-Type natriuretic peptide to distinguish cardiac from noncardiac dyspnea. Am J Cardiol. 2009;104:689–694. https://doi.org/10.1016/j.amjcard.2009.04.043.
  • [29] Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol Ser A Biol Sci Med Sci. 2014;69:S4–S9. https://doi.org/10.1093/gerona/glu057.
  • [30] Porter Starr KN, Orenduff M, McDonald SR, Mulder H, Sloane R, Pieper CF, Bales CW Influence of weight reduction and enhanced protein intake on biomarkers of inflammation in older adults with obesity. J Nutr Gerontol Geriatr. 2019;38:33–49. https://doi.org/10.1080/21551197.2018.1564200.
  • [31] Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13:851–863. https://doi.org/10.5114/aoms.2016.58928.
  • [32] Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PWF, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594–600. https://doi.org/10.1161/01.CIR.0000112582.16683.EA.
  • [33] Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH, de Lemos JA. Impact of body mass and body composition on circulating levels of natriuretic peptides. Circulation. 2005;112:2163–2168. https://doi.org/10.1161/CIRCULATIONAHA.105.555573.
  • [34] Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J. 2005;149:744–750. https://doi.org/10.1016/j.ahj.2004.07.010.
  • [35] Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation: Comparison of the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM). J Hear Lung Transplant. 2011;30:1236–1243. https://doi.org/10.1016/j.healun.2011.05.012.
  • [36] Lamblin N, Mouquet F, Hennache B, Dagorn J, Susen S, Bauters C, de Groote P. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J. 2005;26:2245–2250. https://doi.org/10.1093/eurheartj/ehi501.
  • [37] Yin W-H, Chen J-W, Jen H-L, Chiang M-C, Huang W-P, Feng A-N, Young MS, Lin S-J Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J. 2004;147:931–938. https://doi.org/10.1016/j.ahj.2003.11.021.
  • [38] Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN. C-Reactive Protein in Heart Failure. Circulation. 2005;112:1428–1434. https://doi.org/10.1161/CIRCULATIONAHA.104.508465
  • [39] Araújo JP, Lourenço P, Azevedo A, Friões F, Rocha-Gonçalves F, Ferreira A, Bettencourt P. Prognostic value of high-sensitivity C-Reactive protein in heart failure: A systematic review. J Card Fail. 2009;15:256–266. https://doi.org/10.1016/j.cardfail.2008.10.030.
  • [40] Masson S, Vago T, Baldi G, Salio M, Angelis N De, Nicolis E, Maggioni AP, Latini R, Norbiato G, Bevilacqua M. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med. 2002;40:761–763. https://doi.org/10.1515/CCLM.2002.130.
  • [41] Kuster GM, Tanner H, Printzen G, Suter TM, Mohacsi P HO. B-type natriuretic peptide for diagnosis and treatment of congestive heart failure. Swiss Med Wkly. 2002;132:623–628. https://doi.org/10.4414/smw.2002.10081.
  • [42] Song BG, Jeon ES, Kim YH, Kang MK, Doh JH, Kim PH, Ahn SJ, Oh HL, Kim H-J, Sung JD, Lee SC, Gwon HC, Kim JS, Kim D-K, Lee SH, Hong KP, Park JE, Lee SY, Lee JK. Correlation Between Levels of N-terminal Pro-B-Type Natriuretic Peptide and Degrees of Heart Failure. Korean J Intern Med. 2005;20:26–32. https://doi.org/10.3904/kjim.2005.20.1.26.
  • [43] Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JGF Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J. 2007;153:1048–1055. https://doi.org/10.1016/j.ahj.2007.03.044.
  • [44] Radenovic S, Loncar G, Busjahn A, Apostolovic S, Zdravkovic M, Karlicic V, Veskovic J, Tahirovic E, Butler J, Düngen H-D. Systemic inflammation and functional capacity in elderly heart failure patients. Clin Res Cardiol. 2018;107:362–367. https://doi.org/10.1007/s00392-017-1195-x.
  • [45] Shah SJ, Marcus GM, Gerber IL, Mckeown BH, Vessey JC, Jordan M V., Huddleston M, Foster E, Chatterjee K, Michaels AD. High-Sensitivity C-Reactive Protein and Parameters of Left Ventricular Dysfunction. J Card Fail. 2006;12:61–65. https://doi.org/10.1016/j.cardfail.2005.08.003.
Toplam 45 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Eczacılık ve İlaç Bilimleri (Diğer)
Bölüm Articles
Yazarlar

Busra Nur Cattik

Nilay Aksoy

Barkın Berk

Barış Güngör

Yayımlanma Tarihi 4 Haziran 2025
Gönderilme Tarihi 18 Eylül 2024
Kabul Tarihi 14 Kasım 2024
Yayımlandığı Sayı Yıl 2025 Cilt: 29 Sayı: 3

Kaynak Göster

APA Cattik, B. N., Aksoy, N., Berk, B., Güngör, B. (2025). The association between monocyte/HDL-C ratio and heart failure. Journal of Research in Pharmacy, 29(3), 1089-1097. https://doi.org/10.12991/jrespharm.1694236
AMA Cattik BN, Aksoy N, Berk B, Güngör B. The association between monocyte/HDL-C ratio and heart failure. J. Res. Pharm. Haziran 2025;29(3):1089-1097. doi:10.12991/jrespharm.1694236
Chicago Cattik, Busra Nur, Nilay Aksoy, Barkın Berk, ve Barış Güngör. “The Association Between monocyte/HDL-C Ratio and Heart Failure”. Journal of Research in Pharmacy 29, sy. 3 (Haziran 2025): 1089-97. https://doi.org/10.12991/jrespharm.1694236.
EndNote Cattik BN, Aksoy N, Berk B, Güngör B (01 Haziran 2025) The association between monocyte/HDL-C ratio and heart failure. Journal of Research in Pharmacy 29 3 1089–1097.
IEEE B. N. Cattik, N. Aksoy, B. Berk, ve B. Güngör, “The association between monocyte/HDL-C ratio and heart failure”, J. Res. Pharm., c. 29, sy. 3, ss. 1089–1097, 2025, doi: 10.12991/jrespharm.1694236.
ISNAD Cattik, Busra Nur vd. “The Association Between monocyte/HDL-C Ratio and Heart Failure”. Journal of Research in Pharmacy 29/3 (Haziran 2025), 1089-1097. https://doi.org/10.12991/jrespharm.1694236.
JAMA Cattik BN, Aksoy N, Berk B, Güngör B. The association between monocyte/HDL-C ratio and heart failure. J. Res. Pharm. 2025;29:1089–1097.
MLA Cattik, Busra Nur vd. “The Association Between monocyte/HDL-C Ratio and Heart Failure”. Journal of Research in Pharmacy, c. 29, sy. 3, 2025, ss. 1089-97, doi:10.12991/jrespharm.1694236.
Vancouver Cattik BN, Aksoy N, Berk B, Güngör B. The association between monocyte/HDL-C ratio and heart failure. J. Res. Pharm. 2025;29(3):1089-97.